ストックスクリーナーアプリを入手
432.17
0.55%
2.35
前日終値:
$429.82
開ける：
$432.43
24時間の取引高:
1.15M
Relative Volume:
0.77
時価総額：
$109.65B
収益：
$11.74B
当期純損益:
$3.68B
株価収益率:
30.46
EPS:
14.1888
ネットキャッシュフロー:
$3.34B
1週間 パフォーマンス:
+2.65%
1か月 パフォーマンス:
+2.56%
6か月 パフォーマンス:
-0.88%
1年 パフォーマンス:
-7.47%
1日の値動き範囲:
$428.07
$433.32
1週間の範囲:
$420.00
$435.85
52週間の値動き範囲:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Where Will Vertex Pharmaceuticals Be in 5 Years - AOL.com
Vertex Pharmaceuticals names Wafi Alshehri as HRBP Director for KSA and the GCC - Indiatimes
What Do Analysts Think About Vertex Pharmaceuticals (VRTX)? - Finviz
Interest rate-sensitive biotech companies are bullish on the New York Stock Exchange. Hedge funds ha.. - 매일경제
Scotiabank Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Leads Hedge Fund Interest in Q3 20 - GuruFocus
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon - Finviz
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon - The Motley Fool
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Is Vertex Pharmaceuticals Incorporated a good long term investmentVolatility Index Analysis & Big Returns Low Cost - earlytimes.in
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings - MSN
[Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity - Stock Titan
Shareholder Carney Lloyd Foundation Files To Sell 800 Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
2 Inflation-Proof Growth Stocks That Could Outperform the Market - Finviz
Vertex Nears Historic Breakthrough: Stem Cell Therapy Poised to Transform Type 1 Diabetes Treatment - Azat TV
Vertex Pharmaceuticals Incorporated (0QZU.IL) stock price, news, quote and history - Yahoo Finance UK
How risky is Vertex Pharmaceuticals Incorporated (VX1) stock compared to peers2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataGold Moves & Weekly Chart Analysis and Guides - newser.com
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - Bloomberg Law News
Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Vertex Pharmaceuticals Inc. Stock Falls 3.3%, Underperforms Peers - 富途牛牛
VP Atkinson III Sells 2,500 ($1.1M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3 - Business Wire
Published on: 2025-11-19 14:57:49 - newser.com
Published on: 2025-11-19 14:24:13 - newser.com
Published on: 2025-11-19 03:57:22 - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weakness - newser.com
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trendsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals Incorporated2025 Sector Review & Risk Adjusted Buy/Sell Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingPortfolio Gains Report & Technical Confirmation Trade Alerts - newser.com
A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target - MSN
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November - sharewise.com
Published on: 2025-11-17 18:09:39 - newser.com
Vertex Pharmaceuticals Insider Sold Shares Worth $32,292,320, According to a Recent SEC Filing - MarketScreener
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
Published on: 2025-11-17 12:00:44 - newser.com
VP Atkinson III Files To Sell 2,500 Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
3.56%
大文字化:
|
ボリューム (24 時間):